About Achieve Life Sciences
Achieve Life Sciences (NASDAQ:ACHV) is focused on the development and commercialization of therapies for smoking cessation and nicotine addiction. Its primary project revolves around Cytisinicline, a plant-based alkaloid with the potential to help people quit smoking. By aiming to address the global smoking health epidemic, Achieve Life Sciences is committed to improving overall health outcomes and reducing the burden of smoking-related diseases. Their objective is to provide effective, accessible treatment options that support individuals in their journey to quit smoking and combat nicotine dependence. Through their research and development efforts, Achieve Life Sciences strives to bring innovative solutions to the market, demonstrating their dedication to public health and wellness.
Snapshot
Operations
Products and/or services of Achieve Life Sciences
- Cytisinicline, a smoking cessation aid targeting nicotine addiction.
- Collaborations with academic and research institutions to develop and enhance smoking cessation methods.
- Partnerships for the global commercialization of cytisinicline.
- Research on cytisinicline's effectiveness compared to other smoking cessation aids.
- Development of new formulations and delivery methods for cytisinicline.
- Initiatives to increase awareness and accessibility of smoking cessation solutions.
Achieve Life Sciences executive team
- Dr. Richard A. B. StewartPresident, CEO & Executive Director
- Mr. Mark K. Oki CPAChief Financial Officer
- Mr. Craig DonnellyChief Operations Officer
- Mr. Jerry WanVP of Finance & Principal Accounting Officer
- Mr. Erik AtkissonChief Legal Officer
- Ms. Jaime XinosChief Commercial Officer
- Dr. Mark L. Rubinstein M.D.Chief Medical Officer
- Ms. Nicole P. JonesVice President of Strategic Communications & Stakeholder Relations